↓ Skip to main content

Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma

Overview of attention for article published in Journal for Immunotherapy of Cancer, September 2019
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (83rd percentile)

Mentioned by

twitter
24 tweeters

Citations

dimensions_citation
61 Dimensions

Readers on

mendeley
53 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma
Published in
Journal for Immunotherapy of Cancer, September 2019
DOI 10.1186/s40425-019-0722-x
Pubmed ID
Authors

Mouhammed Amir Habra, Bettzy Stephen, Matthew Campbell, Kenneth Hess, Coya Tapia, Mingxuan Xu, Jordi Rodon Ahnert, Camilo Jimenez, Jeffrey E. Lee, Nancy D. Perrier, Russell R. Boraddus, Shubham Pant, Vivek Subbiah, David S. Hong, Abdulrazzak Zarifa, Siqing Fu, Daniel D. Karp, Funda Meric-Bernstam, Aung Naing

Twitter Demographics

The data shown below were collected from the profiles of 24 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 53 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 53 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 11 21%
Other 7 13%
Student > Ph. D. Student 5 9%
Researcher 5 9%
Student > Doctoral Student 3 6%
Other 13 25%
Unknown 9 17%
Readers by discipline Count As %
Medicine and Dentistry 24 45%
Biochemistry, Genetics and Molecular Biology 5 9%
Agricultural and Biological Sciences 4 8%
Pharmacology, Toxicology and Pharmaceutical Science 2 4%
Unspecified 2 4%
Other 5 9%
Unknown 11 21%

Attention Score in Context

This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 March 2021.
All research outputs
#2,159,096
of 20,443,577 outputs
Outputs from Journal for Immunotherapy of Cancer
#501
of 2,429 outputs
Outputs of similar age
#46,383
of 287,565 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#2
of 2 outputs
Altmetric has tracked 20,443,577 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,429 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.0. This one has done well, scoring higher than 79% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 287,565 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.
We're also able to compare this research output to 2 others from the same source and published within six weeks on either side of this one.